Phase 2 N=33 Hemodynamics and Extravascular Lung Water in Acute Lung Injury
Acute Lung Injury
Primary: The Primary Efficacy Variable Will be the Total Reduction in Measured Lung Water
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Early Insulin and Development of ARDS
Respiratory Distress Syndrome, Adult · Sepsis · Hyperglycemia
Primary: Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen
Phase 2 N=400 LIPS-A: Lung Injury Prevention Study With Aspirin
Acute Respiratory Distress Syndrome
Primary: Number of Participants Who Developed Acute Respiratory Distress Syndrome (ARDS) Within 7 Days — 20; 17 participants — p=0.53
N/A N=139 The Role of Circulating Soluble CD74 in Acute Lung Injury
Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Number of Participants Receiving Mechanical Ventilation — 51; NA participants
Phase 2 N=5 The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury
Lung Injury, Acute
Primary: Heart Rate Assessments Upto Day 7 (Part B) — 87.4; 97.7; 87.9; 95.3 Beats per minute
N/A N=12 Efficacy and Safety of a Lung Recruitment Protocol in Children With Acute Lung Injury
Acute Respiratory Distress Syndrome · Acute Lung Injury
Primary: Oxygenation — 10 Participants
Phase 2 N=77 SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Lung Injury, Acute
Primary: Mean Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell Count — 0.0305; 0.0163; 0.0208; 0.0153…
Phase 2 N=90 A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)
Respiratory Distress Syndrome, Adult · Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8 — 43; -241 pg/mL — p=0.37
Phase 3 N=43 CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients
Acute Lung Injury
Primary: All-cause Mortality at the Time of Pediatric Intensive Care Unit (PICU) Discharge — 15; 6 Participants
N/A N=219 Mechanical Ventilation in the Emergency Department: A Prospective Cross-Sectional Study
Respiratory Failure · Mechanical Ventilation · Acute Lung Injury
Primary: To Further Characterize ED Mechanical Ventilation — 500 mL
Phase 2 N=132 A Randomized Trial of GM-CSF in Patients With ALI/ARDS
Respiratory Distress Syndrome, Adult
Primary: Ventilator-free Days During Days 1-28 — 10.8; 10.7 Days
N/A N=1,705 ED Lung Protective Ventilation to Reduce Complications
Mechanical Ventilation · Ventilator-associated Conditions · ARDS
Primary: Number of Patients That Experience Pulmonary Complications After Admission From the Emergency Department — 171; 38 participants
N/A N=460 Sustained Aeration of Infant Lungs Trial
Preterm Birth · Extreme Prematurity
Primary: Combined Outcome of Death or Bronchopulmonary Dysplasia — 125; 137 Participants
Phase 1 N=18 Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
Sepsis · Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Number of Participants With Adverse Events — 3; 4; 5; 4 Participants
N/A N=125 Families-At-risk for Interstitial Lung Disease Study
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants
N/A N=13 Electrical Impedance Tomography (EIT) Monitoring in Adults With ALI or ARDS
Acute Lung Injury (ALI) · ARDS
Primary: Feasibility of EIT Monitoring in This Population of ARDS/ALI Patients — 13 Patients successfully monitored with EIT
N/A N=34 The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis · Interstitial Pneumonitis
Primary: Change in 6-minute Walk Test Distance (6MWD) — 46.5; 23.2 Meters
Phase 2 N=20 The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)
COVID-19 · Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Primary: Oxygen Index (OI) — -0.91 index
Phase 2 N=165 Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old
Acute Hypoxemic Respiratory Failure
Primary: Duration of Mechanical Ventilation Through 14 Days — 4.0; 4.5 days
Phase 2 N=167 Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury
Acute Lung Injury · Sepsis
Primary: Modified Change in Sequential Organ Failure Assessment (mSOFA) Score — -2.96; -3.20 score on a scale
Phase 2 N=52 Modulation of Lung Injury Complicating Lung Resection
Acute Lung Injury
Primary: Post-operative Plasma IL-6 — 126; 111 pg/ml — p=0.09
Phase 4 N=40 Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach
Hypotension · Kidney Injury
Primary: Development of Renal Injury — 0.8; 0.74 mg/dL — p=0.31
Phase 2 N=10 Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
Restrictive Chronic Lung Allograft Dysfunction · Lung Transplant Rejection
Primary: Tolerability of Pirfenidone — 3 Participants
N/A N=320 Intensive Alveolar Recruitment Protocol After Cardiac Surgery
Ventilator Induced Lung Injury · Cardiac Disease · Acute Lung Injury
Primary: Severity of Pulmonary Complications in the Post-operative Period — 15; 26 percentage of participants — p=0.016
N/A N=207 Autologous Stem Cell Treatment for Chronic Lung Disease Study
COPD · Interstitial Lung Disease
Primary: Change in FEV1 From Baseline Among COPD Patients — 12.8 percentage of change in FEV1
N/A N=489 An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease
COPD · Interstitial Lung Disease
Primary: Change in Quality of Life (QOL) From Baseline — 35.35; 27.96; 26.87 score on a scale
N/A N=65 Ventilator-induced Lung Injury Vortex in Patients With SARS-CoV-2
ARDS · Mechanical Ventilation Complication · Ventilator-Induced Lung Injury
Primary: Number of Participants Who Survived and Died — 1; 31; 14; 19 Participants
Phase 2 N=37 Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II
Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Clinically Significant Treatment Emergent Events — 37; 30; 22; 20 Number of patients
Phase 2 N=61 LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
Acute Respiratory Distress Syndrome (ARDS)
Primary: Change in Oxygen Saturation to Fraction of Inspired Oxygen Concentration (SpO2/FiO2) Ratio — 320; 334; 376; 336 SpO2/FiO2 Ratio — p=0.02
N/A N=50 Extracorporeal Lung Assist to Avoid Intubation in Patients Failing Noninvasive Ventilation for Hypercapnic ARF
Hypercapnia · Respiratory Insufficiency
Primary: Number of Patients With Need for Intubation for Invasive Mechanical Ventilation — 11; 25 Participants